Nurix therapeutics reports first clinical evidence of cns activity of nx-5948, a brain-penetrant, orally available, btk degrader in development for b cell malignancies

Presented new case studies demonstrating clinical responses in two patients with b cell malignancies, chronic lymphocytic leukemia (cll) and primary central nervous system lymphoma (pcnsl), each with central nervous system (cns) involvement

NRIX Ratings Summary

NRIX Quant Ranking